Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.

ClinicalTrials.gov ID: NCT00326326

Public ClinicalTrials.gov record NCT00326326. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 24, 2026, 4:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Effect Of CP-778,875 On HDL-Cholesterol In Adult Subjects With Dyslipidemia And Type 2 Diabetes Mellitus

Study identification

NCT ID
NCT00326326
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
84 participants

Conditions and interventions

Conditions

Interventions

  • CP-778,875 Drug

Drug

Eligibility (public fields only)

Age range
30 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2006
Primary completion
Not listed
Completion
May 31, 2007
Last update posted
May 6, 2009

2006 – 2007

United States locations

U.S. sites
31
U.S. states
18
U.S. cities
29
Facility City State ZIP Site status
Pfizer Investigational Site Anniston Alabama 36207
Pfizer Investigational Site Huntsville Alabama 35801
Pfizer Investigational Site Greenbrae California 94904
Pfizer Investigational Site Los Angeles California 90057
Pfizer Investigational Site Walnut Creek California 94598
Pfizer Investigational Site DeFuniak Springs Florida 32435
Pfizer Investigational Site Destin Florida 32541
Pfizer Investigational Site Jupiter Florida 33458
Pfizer Investigational Site Melbourne Florida 32901
Pfizer Investigational Site Atlanta Georgia 30342
Pfizer Investigational Site Conyers Georgia 30094
Pfizer Investigational Site Chicago Illinois 60612
Pfizer Investigational Site Iowa City Iowa 52242
Pfizer Investigational Site Lexington Kentucky 40504
Pfizer Investigational Site Baltimore Maryland 21201
Pfizer Investigational Site Springfield Missouri 65807
Pfizer Investigational Site Omaha Nebraska 68131
Pfizer Investigational Site Las Vegas Nevada 89106
Pfizer Investigational Site Mount Vernon New York 10550
Pfizer Investigational Site Oklahoma City Oklahoma 73103
Pfizer Investigational Site Tulsa Oklahoma 74136
Pfizer Investigational Site Kingsport Tennessee 37660
Pfizer Investigational Site Bryan Texas 77802
Pfizer Investigational Site Houston Texas 77030
Pfizer Investigational Site San Antonio Texas 78229
Pfizer Investigational Site Newport News Virginia 23606
Pfizer Investigational Site Richmond Virginia 23225
Pfizer Investigational Site Richmond Virginia 23249
Pfizer Investigational Site Richmond Virginia 23294
Pfizer Investigational Site Yakima Washington 98902
Pfizer Investigational Site Milwaukee Wisconsin 53209

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00326326, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 6, 2009 · Synced Jul 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00326326 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →